Sign In
Buy FATE
$2.45
-0.0600 (-2.39%)
At Close: Jul 31, 2026
Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know
01:41pm, Wednesday, 03'rd May 2023
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
08:00am, Monday, 24'th Apr 2023
SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a
Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report?
12:56pm, Thursday, 30'th Mar 2023
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:57am, Monday, 27'th Mar 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Fate Therapeutics to Present at Upcoming March Investor Conferences
04:01pm, Friday, 03'rd Mar 2023
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a
Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Call Transcript
10:57pm, Tuesday, 28'th Feb 2023
Fate Therapeutics, Inc. (NASDAQ:FATE ) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Chief Medica
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Tuesday, 28'th Feb 2023
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 32.56% and 124.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The 5 Best and Worst Performing Small-Cap Stocks in January 2023
10:51pm, Monday, 13'th Feb 2023
Small-cap stocks are expected to perform well this year. The Bank of America Securities, in fact, is asking investors to consider small caps this year to hedge against a declining market.
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results
08:00am, Monday, 13'th Feb 2023
SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
04:03am, Thursday, 26'th Jan 2023
The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.
Down -52.57% in 4 Weeks, Here's Why Fate Therapeutics (FATE) Looks Ripe for a Turnaround
11:18am, Thursday, 19'th Jan 2023
Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings e
5 Best and Worst Performing Small-Cap Stocks in Dec 2022
10:59pm, Tuesday, 17'th Jan 2023
Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
07:33am, Tuesday, 10'th Jan 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
03:48pm, Friday, 06'th Jan 2023
Layoffs have been making headlines so far in 2023, even though we're just a few days into the new year. That's true even for gene-editing stocks.
FATE To End Janssen Deal and Prioritize Pipeline Development
03:03pm, Friday, 06'th Jan 2023
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
